HomeCompareASCLF vs MAIN

ASCLF vs MAIN: Dividend Comparison 2026

ASCLF yields 110.50% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $42.02M in total portfolio value· pulled ahead in Year 9
10 years
ASCLF
ASCLF
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full ASCLF calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — ASCLF vs MAIN

📍 MAIN pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCLFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCLF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASCLF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCLF
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $32,364,488.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCLF + MAIN for your $10,000?

ASCLF: 50%MAIN: 50%
100% MAIN50/50100% ASCLF
Portfolio after 10yr
$26.94M
Annual income
$21,170,765.00/yr
Blended yield
78.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

ASCLF
No analyst data
Altman Z
61.0
Piotroski
1/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCLF buys
0
MAIN buys
0
No recent congressional trades found for ASCLF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCLFMAIN
Forward yield110.50%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$5.93M$47.95M
Annual income after 10y$2,132,830.87$40,208,699.11
Total dividends collected$5.35M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: ASCLF vs MAIN ($10,000, DRIP)

YearASCLF PortfolioASCLF Income/yrMAIN PortfolioMAIN Income/yrGap
1$21,750$11,049.72$12,464$1,223.78+$9.3KASCLF
2$45,733$22,460.60$16,353$2,343.58+$29.4KASCLF
3$93,072$44,137.91$23,105$4,724.42+$70.0KASCLF
4$183,537$83,949.70$36,226$10,256.23+$147.3KASCLF
5$351,102$154,717.47$65,426$24,707.64+$285.7KASCLF
6$652,287$276,608.54$142,101$68,562.02+$510.2KASCLF
7$1,178,220$480,272.57$388,521$228,799.95+$789.7KASCLF
8$2,071,454$810,758.34$1,397,868$961,169.80+$673.6KASCLF
9← crossover$3,548,616$1,332,160.25$6,884,663$5,313,459.69$3.34MMAIN
10$5,929,850$2,132,830.87$47,947,060$40,208,699.11$42.02MMAIN

ASCLF vs MAIN: Complete Analysis 2026

ASCLFStock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Full ASCLF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this ASCLF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCLF vs SCHDASCLF vs JEPIASCLF vs OASCLF vs KOASCLF vs ARCCASCLF vs HTGCASCLF vs GBDCASCLF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.